CompuMed, Inc. (CMPD) Stock Analysis

CompuMed, Inc. (CMPD) Healthcare & Pipeline Overview

CompuMed, Inc. is an enterprise telemedicine solutions provider delivering telecardiology and teleradiology services globally via cloud-based technology and integrated medical devices. It offers real-time access to U.S. Board-Certified specialists, serving critical sectors like organ procurement, rural, and correctional healthcare with diagnostic interpretations and mobile solutions.

What Is the Investment Thesis for CMPD?

CompuMed, Inc. operates in the expanding telemedicine sector, offering specialized telecardiology and teleradiology services that leverage cloud-based technology and U.S. Board-Certified specialists. The company's unique value proposition lies in providing real-time access to expert diagnostics for underserved markets such as rural, correctional, and organ procurement organizations. Key growth catalysts include the increasing global demand for remote healthcare solutions, driven by specialist shortages and geographical barriers, and the potential for wider adoption of its specialized OsteoGram software for osteoporosis screening. The company's gross margin of 47.1% indicates efficiency in its service delivery model. However, investors must consider the company's micro-cap status with a market capitalization of $8.77M and a negative profit margin of -3.1%, signaling current unprofitability. Its Beta of -0.53 suggests lower market volatility, potentially due to its niche operations or limited trading. The company's listing on the OTC Other tier also introduces risks related to liquidity and disclosure transparency, which are critical factors for detailed investor analysis.

Based on FMP financials and quantitative analysis

CMPD Key Highlights

Market Capitalization: $8.77M, indicating a micro-cap company with a very small market footprint.

• Gross Margin: 47.1%, suggesting efficient cost management relative to revenue generated from its specialized telemedicine services.
• Profit Margin: -3.1%, reflecting current unprofitability in its operations, which warrants close monitoring of financial performance.
• Beta: -0.53, suggesting lower volatility compared to the broader market, potentially due to its niche service offerings or limited trading volume.
• Employee Count: 8 employees, highlighting a lean operational structure for a company providing global telemedicine solutions.

What Are CMPD's Key Strengths?

Proprietary cloud-based technology for secure and real-time diagnostic services.

• Access to a network of U.S. Board-Certified specialists for expert interpretations.
• Diverse service offerings in telecardiology and teleradiology, covering multiple modalities.
• Specialized OsteoGram software for osteoporosis screening, addressing a niche market need.
• Established presence and tailored solutions for underserved markets (organ procurement, rural, correctional healthcare).

What Are CMPD's Weaknesses?

Very small market capitalization ($8.77M) indicating limited scale and financial resources.

• Persistent negative profit margin (-3.1%) reflecting current unprofitability.
• Lean operational structure with only 8 employees, potentially limiting scalability and rapid expansion.
• Listing on the OTC Other tier, which implies lower transparency and potential liquidity challenges.
• Unknown disclosure status, hindering comprehensive investor due diligence and financial assessment.

What Could Drive CMPD Stock Higher?

Increasing global adoption of telemedicine solutions, driven by technological advancements and healthcare accessibility needs.

• Expansion of service contracts within underserved markets, particularly rural and correctional healthcare, leveraging existing expertise.
• Potential new partnerships or collaborations for broader deployment of the OsteoGram software in new clinical settings.
• Introduction of enhanced mobile diagnostic devices or software features to expand the reach and capabilities of existing solutions.
• Favorable regulatory developments in telemedicine reimbursement or cross-border medical service provision.

What Are the Key Risks for CMPD?

Financial-distress signal — its Altman Z-Score of -4.93 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-8.1%) — the business is not currently generating profit on shareholder capital.
• Insider selling — insiders were net sellers of roughly $3.8M recently.
• Sustained negative profit margin of -3.1% impacting financial stability and long-term operational viability.
• Intense competition from well-capitalized healthcare technology companies with broader service portfolios and market reach.
• Regulatory changes in telemedicine, data privacy (e.g., HIPAA), or medical device approvals affecting operations and compliance costs.
• Challenges in attracting and retaining U.S. Board-Certified specialists necessary for service delivery, impacting capacity and quality.
• Liquidity and transparency issues inherent with its OTC Other market listing, posing risks for investors seeking to trade shares.

What Are the Growth Opportunities for CMPD?

• Expansion of Telecardiology Services: The global demand for remote cardiac diagnostics continues to rise, driven by an aging population, increasing prevalence of cardiovascular diseases, and a shortage of cardiologists. CompuMed can capitalize on this by expanding its telecardiology service offerings, potentially through strategic partnerships with larger healthcare networks or by targeting additional underserved regions. The market for remote cardiac monitoring and diagnostics is projected to grow significantly, offering CompuMed a substantial opportunity to increase its service volume and market share by emphasizing its real-time access to U.S. Board-Certified specialists.
• Teleradiology Market Penetration: With the increasing volume of medical imaging and the need for rapid, expert interpretations, the teleradiology market presents a robust growth avenue. CompuMed's comprehensive teleradiology services, covering various modalities from X-ray to MRI, can be expanded by securing more contracts with hospitals and imaging centers, especially those in remote areas or those experiencing staffing challenges. Focusing on efficient turnaround times and the quality of U.S. Board-Certified interpretations can differentiate CompuMed in a competitive market, allowing it to capture a larger share of the growing global teleradiology services market.
• OsteoGram Software Adoption: CompuMed's OsteoGram software, designed for osteoporosis screening, diagnosis, and therapy monitoring, addresses a critical public health need. Osteoporosis affects millions globally, and early detection is crucial. By intensifying marketing efforts and demonstrating the cost-effectiveness and diagnostic accuracy of OsteoGram, CompuMed can drive wider adoption among clinics, hospitals, and specialized bone health centers. This proprietary software offers a unique competitive advantage, and expanding its user base could significantly contribute to revenue growth, particularly as healthcare systems prioritize preventive care and chronic disease management.
• Mobile Telemedicine Solutions: The proliferation of mobile health technologies offers a substantial opportunity for CompuMed. Its existing mobile ECG and ultrasound solutions provide immediate access to specialists, which is highly valuable in emergency settings, remote locations, and for home-based care. Expanding the capabilities and reach of these mobile solutions, potentially through partnerships with mobile network providers or by developing more portable and user-friendly devices, could tap into the rapidly growing mobile health market. This would enhance patient convenience and accessibility, fostering growth in areas where traditional diagnostic access is challenging.
• Targeted Industry Expansion: CompuMed's current focus on organ procurement organizations, rural healthcare, and correctional healthcare industries provides a strong foundation. These are often underserved sectors with unique needs for specialized, remote diagnostic services. Expanding within these existing niches by offering more integrated solutions or by identifying adjacent specialized healthcare segments, such as long-term care facilities or military healthcare, could unlock significant growth. Leveraging its established expertise and reputation in these specific markets allows CompuMed to pursue targeted expansion without directly competing with larger, more generalized telemedicine providers.

What Threats Does CMPD Face?

• Intense competition from larger, well-funded healthcare technology companies with broader market reach.
• Evolving regulatory landscape for telemedicine and data privacy, potentially increasing compliance costs.
• Reliance on the availability and retention of U.S. Board-Certified specialists.
• Technological obsolescence requiring continuous investment in R&D to remain competitive.
• Economic downturns or changes in healthcare reimbursement policies impacting demand for services.

What Are CMPD's Competitive Advantages?

• Proprietary cloud-based technology platform enabling secure and real-time transmission of medical data.
• Network of U.S. Board-Certified specialists providing expert diagnostic interpretations, a critical resource.
• Specialized OsteoGram software for osteoporosis screening, offering a niche diagnostic solution.
• Integrated medical devices that streamline the telemedicine workflow and enhance service delivery.
• Established expertise and presence in specific, often underserved, markets like rural and correctional healthcare.

What Does CMPD Do?

CompuMed, Inc., founded in 1973 and headquartered in Los Angeles, California, has evolved into a dedicated enterprise telemedicine solutions company. Initially established in the medical technology space, the company has strategically shifted its focus to leveraging digital advancements to deliver critical clinical care services remotely. At its core, CompuMed provides specialized telecardiology and teleradiology services, enabling medical facilities worldwide to access U.S. Board-Certified specialists in real-time. This is achieved through a robust cloud-based technology platform integrated with advanced medical devices, ensuring efficient and secure transmission of diagnostic data. The company's comprehensive suite of telecardiology services encompasses diagnostic exam interpretations for both pediatric and adult patients, covering a wide array of procedures including electrocardiograms (ECG), echocardiograms, vascular studies, Holter monitoring, nuclear cardiology, and video consultations. Similarly, its teleradiology offerings are extensive, providing reading, transcription, reporting, storage, and video consultations across various imaging modalities such as Vscan, X-ray, ultrasound, mammography, computed tomography (CT), and magnetic resonance imaging (MRI). Beyond these core services, CompuMed also develops and markets OsteoGram software, a specialized tool that works in conjunction with standard or digital X-ray equipment to facilitate osteoporosis screening, diagnosis, and therapy monitoring. Furthermore, the company offers mobile ECG and ultrasound solutions, designed to provide patients with immediate access to its network of board-certified specialists, enhancing accessibility to crucial diagnostics. CompuMed primarily serves specialized and often underserved markets, including organ procurement organizations, rural healthcare facilities, and correctional healthcare industries, positioning itself as a vital partner in expanding access to expert medical diagnostics.

What Products and Services Does CMPD Offer?

• Provide enterprise telemedicine solutions for clinical care services.
• Offer telecardiology services including ECG, echocardiogram, vascular, holter, nuclear, and video consults.
• Deliver teleradiology services for X-ray, ultrasound, mammography, CT, MRI, Vscan, and radiologist video consults.
• Grant real-time access to U.S. Board-Certified specialists through cloud-based technology.
• Develop and market OsteoGram software for osteoporosis screening, diagnosis, and therapy monitoring.
• Provide mobile ECG and ultrasound solutions for immediate patient access to specialists.
• Integrate cloud-based technology with medical devices to facilitate remote diagnostics.
• Serve specialized industries such as organ procurement organizations, rural healthcare, and correctional healthcare.

How Does CMPD Make Money?

• Generates revenue through service fees for telecardiology and teleradiology diagnostic interpretations.
• Earns income from licensing and maintenance fees for its OsteoGram software.
• Sells integrated medical devices that complement its telemedicine platforms.
• Receives fees for specialist video consultations and remote patient monitoring services.
• Secures enterprise contracts with medical facilities and organizations for comprehensive telemedicine solutions.

What Industry Does CMPD Operate In?

CompuMed, Inc. operates within the dynamic and rapidly expanding Medical - Healthcare Information Services industry, specifically focusing on enterprise telemedicine solutions. The global telemedicine market is experiencing significant growth, driven by technological advancements, increasing demand for remote patient monitoring, and the persistent shortage of medical specialists in many regions. CompuMed carves out a niche by providing specialized telecardiology and teleradiology services, offering real-time access to U.S. Board-Certified specialists through its cloud-based platform. While the competitive landscape includes larger, more diversified healthcare technology companies, CompuMed differentiates itself by targeting specific underserved segments such as organ procurement organizations, rural healthcare, and correctional facilities. The company's integrated approach, combining proprietary software like OsteoGram with medical devices, positions it to capitalize on the ongoing shift towards digital health and remote diagnostics, particularly in areas where access to specialized care is limited.

Who Are CMPD's Key Customers?

• Medical facilities and hospitals worldwide.
• Organ procurement organizations requiring rapid diagnostic support.
• Rural healthcare providers seeking access to specialized medical expertise.
• Correctional healthcare industries for inmate medical diagnostics.
• Pediatric and adult patients, who are indirect beneficiaries of services provided to facilities.

The most recent 11 insider filings for CompuMed, Inc. break down as 7 sales and 4 purchases. On net that is roughly 28.6M shares disposed (about $3.8M), a signal worth weighing alongside the fundamentals.

CompuMed, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -4.93 places it in the distress zone, a signal of elevated financial risk.

Return on equity for CompuMed, Inc. stands at -8.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 5.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.3%, the inverse of the P/E and a quick read on earnings relative to price.

CompuMed, Inc. (CMPD) Valuation Context

Valued at $8.77M, CMPD is classified as a micro-cap stock.

CMPD Revenue & Earnings Trend

In Q3 FY2026, CMPD generated $2.2M in top-line revenue, marking a sequential increase of 6.2%. The company recorded net income of $25K, with diluted EPS of $0.02. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CMPD averaged $-0.05 in diluted EPS.

Company Profile

CompuMed, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Lee Keddie. CMPD has traded publicly since 1987.

CMPD Financials

CMPD Latest News

CMPD Analyst Consensus

CMPD MoonshotScore

Common Questions About CMPD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources